ABBV vs. GE: A Head-to-Head Stock Comparison

Updated on October 8, 2025

Here’s a clear look at ABBV and GE, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ABBV	GE
Company Name	AbbVie Inc.	GE Aerospace
Country	United States	United States
GICS Sector	Health Care	Industrials
GICS Industry	Biotechnology	Industrial Conglomerates
Market Capitalization	406.64 billion USD	316.24 billion USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	January 2, 1962
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ABBV and GE by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. GE: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	GE
5-Day Price Return	-0.58%	-0.86%
13-Week Price Return	22.68%	19.94%
26-Week Price Return	11.60%	46.34%
52-Week Price Return	17.77%	62.17%
Month-to-Date Return	-0.58%	-0.86%
Year-to-Date Return	29.54%	78.80%
10-Day Avg. Volume	7.35M	3.73M
3-Month Avg. Volume	5.73M	5.60M
3-Month Volatility	24.02%	21.05%
Beta	0.36	1.44

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

GE

40.51%

Industrial Conglomerates Industry

Max: 21.93%
Q3: 13.64%
Median: 9.41%
Q1: 5.80%
Min: -3.73%

GE’s Return on Equity of 40.51% is exceptionally high, placing it well beyond the typical range for the Industrial Conglomerates industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

ABBV vs. GE: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

GE

18.64%

Industrial Conglomerates Industry

Max: 26.43%
Q3: 13.08%
Median: 9.39%
Q1: 3.21%
Min: -2.43%

A Net Profit Margin of 18.64% places GE in the upper quartile for the Industrial Conglomerates industry, signifying strong profitability and more effective cost management than most of its peers.

ABBV vs. GE: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

GE

15.53%

Industrial Conglomerates Industry

Max: 27.02%
Q3: 17.23%
Median: 12.90%
Q1: 8.32%
Min: -3.91%

GE’s Operating Profit Margin of 15.53% is around the midpoint for the Industrial Conglomerates industry, indicating that its efficiency in managing core business operations is typical for the sector.

ABBV vs. GE: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Profitability at a Glance

Symbol	ABBV	GE
Return on Equity (TTM)	95.59%	40.51%
Return on Assets (TTM)	2.73%	6.22%
Net Profit Margin (TTM)	6.45%	18.64%
Operating Profit Margin (TTM)	18.80%	15.53%
Gross Profit Margin (TTM)	70.93%	35.97%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

GE

1.04

Industrial Conglomerates Industry

Max: 2.40
Q3: 1.69
Median: 1.35
Q1: 1.14
Min: 0.56

GE’s Current Ratio of 1.04 falls into the lower quartile for the Industrial Conglomerates industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ABBV vs. GE: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

GE

0.99

Industrial Conglomerates Industry

Max: 2.27
Q3: 1.49
Median: 0.91
Q1: 0.63
Min: 0.24

GE’s Debt-to-Equity Ratio of 0.99 is typical for the Industrial Conglomerates industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABBV vs. GE: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

GE

5.01

Industrial Conglomerates Industry

Max: 19.80
Q3: 10.68
Median: 4.59
Q1: 2.73
Min: -2.15

GE’s Interest Coverage Ratio of 5.01 is positioned comfortably within the norm for the Industrial Conglomerates industry, indicating a standard and healthy capacity to cover its interest payments.

ABBV vs. GE: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	GE
Current Ratio (MRQ)	0.74	1.04
Quick Ratio (MRQ)	0.48	0.73
Debt-to-Equity Ratio (MRQ)	49.22	0.99
Interest Coverage Ratio (TTM)	2.70	5.01

Growth

Revenue Growth

ABBV vs. GE: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. GE: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.74%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.74% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

GE

0.41%

Industrial Conglomerates Industry

Max: 9.82%
Q3: 5.04%
Median: 3.09%
Q1: 1.67%
Min: 0.00%

GE’s Dividend Yield of 0.41% is in the lower quartile for the Industrial Conglomerates industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

ABBV vs. GE: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

GE

16.78%

Industrial Conglomerates Industry

Max: 182.48%
Q3: 97.89%
Median: 55.48%
Q1: 31.63%
Min: 1.76%

GE’s Dividend Payout Ratio of 16.78% is in the lower quartile for the Industrial Conglomerates industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

ABBV vs. GE: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Dividend at a Glance

Symbol	ABBV	GE
Dividend Yield (TTM)	2.74%	0.41%
Dividend Payout Ratio (TTM)	226.84%	16.78%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

109.81

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

At 109.81, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

GE

40.72

Industrial Conglomerates Industry

Max: 45.17
Q3: 25.68
Median: 15.16
Q1: 8.58
Min: 0.79

A P/E Ratio of 40.72 places GE in the upper quartile for the Industrial Conglomerates industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

ABBV vs. GE: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.08

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ABBV’s P/S Ratio of 7.08 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

GE

7.59

Industrial Conglomerates Industry

Max: 4.18
Q3: 2.15
Median: 0.69
Q1: 0.41
Min: 0.09

With a P/S Ratio of 7.59, GE trades at a valuation that eclipses even the highest in the Industrial Conglomerates industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

ABBV vs. GE: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

GE

14.26

Industrial Conglomerates Industry

Max: 5.44
Q3: 2.68
Median: 0.97
Q1: 0.52
Min: 0.04

At 14.26, GE’s P/B Ratio is at an extreme premium to the Industrial Conglomerates industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ABBV vs. GE: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Industrial Conglomerates industry benchmarks.

Valuation at a Glance

Symbol	ABBV	GE
Price-to-Earnings Ratio (TTM)	109.81	40.72
Price-to-Sales Ratio (TTM)	7.08	7.59
Price-to-Book Ratio (MRQ)	261.01	14.26
Price-to-Free Cash Flow Ratio (TTM)	22.66	57.50